Blog
RSS FeedPosted by Michael Wonder on 04 Nov 2022
AVITA Medical announces FDA breakthrough device designations for the Recell system
3 November 2022 - AVITA Medical announced today that the FDA granted the Recell system designations as a breakthrough device for ...
Posted by Michael Wonder on 03 Nov 2022
Rhythm Pharmaceuticals announces setmelanotide granted breakthrough therapy designation for hypothalamic obesity by the US FDA
1 November 2022 - Rhythm Pharmaceuticals today announced that setmelanotide received breakthrough therapy designation from the US FDA for the treatment ...
Posted by Michael Wonder on 03 Nov 2022
Pfizer’s elranatamab granted FDA breakthrough therapy designation for relapsed or refractory multiple myeloma
3 November 2022 - Breakthrough therapy designation based on updated data from Phase 2 MagnetisMM-3 study that showed an overall response ...
Posted by Michael Wonder on 26 Oct 2022
CorVista Health receives breakthrough device designation for the CorVista system
25 October 2022 - CorVista Health announces that the US FDA has granted breakthrough device designation for the CorVista System as ...
Posted by Michael Wonder on 25 Oct 2022
EndoStim receives FDA breakthrough device designation for the EndoStim system for the treatment of drug refractory GERD
25 October 2022 - EndoStim announced today that the US FDA granted breakthrough device designation for the Company’s EndoStim system. ...
Posted by Michael Wonder on 21 Oct 2022
Akeso's ivonescimab granted breakthrough therapy designation by China NMPA for the treatment of advanced NSCLC
20 October 2022 - Akeso announced that the Center for Drug Evaluation of China NMPA has granted breakthrough therapy designation ...
Posted by Michael Wonder on 20 Oct 2022
Sinaptica Therapeutics announces FDA breakthrough device designation for its novel non-invasive neurostimulation treatment for Alzheimer’s disease
19 October 2022 - Breakthrough designation is based on positive outcomes from a Phase 2 clinical trial in mild to ...
Posted by Michael Wonder on 18 Oct 2022
Axoft brain implant technology is granted FDA breakthrough device designation
18 October 2022 - Axoft today launched and announced FDA breakthrough device designation for its brain-machine interface to better treat ...
Posted by Michael Wonder on 12 Oct 2022
FDA will begin accepting breakthrough devices for TAP pilot in 2023
11 October 2022 - The US FDA will start accepting products into its total product lifecycle advisory program (TAP) pilot starting ...
Posted by Michael Wonder on 07 Oct 2022
Desktop Health receives FDA clearance for SmileGuard resin for durable and comfortable orthodontic and dental appliances
6 October 2022 - Dentists and labs can use proprietary SmileGuard resin to 3D print bite splints, night guards, and mouth ...
Posted by Michael Wonder on 20 Sep 2022
XVIVO granted breakthrough device designation from the FDA for the liver assist device
20 September 2022 - XVIVO Perfusion has been granted breakthrough device designation from the US FDA for their liver assist device, ...
Posted by Michael Wonder on 14 Sep 2022
Potrero Medical receives FDA breakthrough device designation for Accuryn AKI predict algorithm
13 September 2022 - Potrero Medical announced today that the FDA granted breakthrough device designation for their AKI Predict machine learning ...
Posted by Michael Wonder on 12 Sep 2022
FDA grants breakthrough device designation for CurveBeam AI's OssView bone fragility software
12 September 2022 - CurveBeam announced its medical diagnostic software, OssView, has received US FDA breakthrough device designation. ...
Posted by Michael Wonder on 08 Sep 2022
Ceribell receives FDA breakthrough device designation for delirium indication
8 September 2022 - Breakthrough device designation recognizes Ceribell's point of care EEG as a first of its kind technology ...
Posted by Michael Wonder on 07 Sep 2022
FDA grants breakthrough therapy designation to Pfizer’s Group B Streptococcus vaccine candidate to help prevent infection in infants via immunisation of pregnant women
7 September 2022 - Pfizer today announced that its investigational Group B Streptococcus vaccine candidate, GBS6 or PF-06760805, received breakthrough ...